Vaxcyte
PCVX
83 hedge funds and large institutions have $1.12B invested in Vaxcyte in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 5 closing their positions.
460% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 14
38% more funds holding
Funds holding: 60 → 83 (+23)
8.79% more ownership
Funds ownership: 74.16% → 82.95% (+8.8%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
40% less capital invested
Capital invested by funds: $1.86B → $1.12B (-$738M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$47.1M |
| 2 |
BlackRock
New York
|
+$25.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$24.1M |
| 4 |
Millennium Management
New York
|
+$12.3M |
| 5 |
Goldman Sachs
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$58.5M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.71M |
| 3 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$8.01M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.23M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$988K |
PCVX Hedge Fund Activity: Q4 2020 in Review
83 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2020, worth a combined $1.12B — down 40% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PCVX positions and 5 closed out — a net gain of 23 holders — while 28 added to existing stakes and 14 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $47.1M. The largest seller was RA Capital Management, cutting an estimated $58.5M.
- 83 institutional investors held Vaxcyte (PCVX) as of Q4 2020, up from 60 in Q3 2020.
- Funds reported $1.12B of Vaxcyte stock for Q4 2020, down 40% quarter-over-quarter.
- 28 funds opened new Vaxcyte positions in Q4 2020 and 5 closed out, a net change of +23 holders.
- The largest Vaxcyte buyer in Q4 2020 was Fidelity Investments, an estimated $47.1M added.
- The largest Vaxcyte seller in Q4 2020 was RA Capital Management, an estimated $58.5M sold.
Based on aggregated 13F filings for Q4 2020.